Corona Remedies Limited
₹2,146.05-₹69.00 (-3.1%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹8,749 Cr
- P/E
- 55.1x
- EV / EBITDA
- 55.0x
- Revenue
- ₹1,196 Cr
- Net margin
- 8.9%
- ROCE
- 24.4%
Price chart
Technical chartScreen technicals →+49.3% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +2.5%
- 3M
- +2.7%
- 6M
- +24.4%
- 1Y
- +49.3%
- 5Y
- +56.1%
52-week range
Day change -₹69.00 (-3.1%) from ₹2,215 to ₹2,146 · Last close Oct 30, 2026
AI Summary
Indian StockStrengths1
- Healthy return on equity of 18.8%
Concerns0
Rule-based from financial data. Not advice.
About the company
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
- Sector
- Healthcare
- Shares outstanding
- 6.1 Cr shares
- ISIN
- INE02ZQ01018
- BSE code
- 544644
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹8,749 Cr
- P/E
- 55.1x
- EV / EBITDA
- 55.0x
- EV / Sales
- 8.7x
- P/S
- 8.6x
- Earnings yield
- 1.8%
- 52-week high
- ₹2,236.30
- 52-week low
- ₹1,347.25
Profitability
- Operating margin
- 15.4%
- Net margin
- 8.9%
- EBITDA margin
- 15.9%
- ROE
- 18.8%
- ROCE
- 24.4%
- ROA
- 10.8%
- Dividend payout
- 25.0%
- Tax rate
- 24.0%
- Other income, % of PBT
- 4.2%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,196 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 17.9%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 11.0%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹161 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 19.3%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 65.6%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 8.8%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹157 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 52.4%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹11.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 39.5%
Solvency and efficiency
- Current ratio
- 1.71
- Debt / Equity
- 0.33
- Debt / Assets
- 0.19
- Debt / EBITDA
- 0.99
- Interest coverage
- 11.14
- Financial leverage
- 1.73
- CFO / Net profit
- 1.74
- Cash / Market cap
- 3.4%
- Cash per share
- ₹49.30
- Asset turnover
- 1.22
- Fixed asset turnover
- 2.64
- Capital intensity
- 0.38
- Debtor days
- 36 days
- Inventory turnover
- 2.31
- Cash conversion cycle
- 10 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹12 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹955 Cr |
| Sales | Operating profit | ₹241 Cr |
| Operating profit | Interest | ₹11 Cr |
| Operating profit | Depreciation | ₹37 Cr |
| Operating profit | Profit before tax | ₹193 Cr |
| Other income | Profit before tax | ₹5 Cr |
| Profit before tax | Tax and other | ₹49 Cr |
| Profit before tax | Net profit | ₹149 Cr |
Revenue and net profit
Revenue grew 17.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹576 Cr | ₹70 Cr |
| FY2022 | ₹617 Cr | ₹0 Cr |
| FY2023 | ₹884 Cr | ₹85 Cr |
| FY2024 | ₹1,014 Cr | ₹90 Cr |
| FY2025 | ₹1,196 Cr | ₹149 Cr |
Cash flows
FY2025: ₹190 Cr from operations, ₹106 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹79 Cr | -₹23 Cr |
| FY2022 | ₹98 Cr | ₹32 Cr |
| FY2023 | ₹103 Cr | ₹53 Cr |
| FY2024 | ₹157 Cr | -₹110 Cr |
| FY2025 | ₹190 Cr | ₹106 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,196 Cr+17.9%1Y
- Net profit
- ₹149 Cr+65.6%1Y
- Cash from operations
- ₹190 Cr
- Free cash flow
- ₹106 Cr
- Revenue CAGR, 5Y
- 11.0%
- EBITDA CAGR, 5Y
- 10.9%
- Net profit CAGR, 5Y
- 8.8%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,196 Cr | ₹241 Cr | — | ₹149 Cr | ₹190 Cr | ₹106 Cr | 24.6% | +17.9% | +65.6% |
Monthly returns
Month-by-month returns of CORONA across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹929 Cr |
| Equity capital | ₹61 Cr |
| Reserves | ₹545 Cr |
| Borrowings | ₹86 Cr |
| Other liabilities | ₹237 Cr |
| Assets | ₹929 Cr |
| Fixed assets | ₹370 Cr |
| Capital work in progress | ₹186 Cr |
| Investments | ₹25 Cr |
| Other assets | ₹348 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
CORONA trades at 55.1x earnings against a peer median of 52.6x.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Corona Remedies LimitedCORONAthis company | ₹8,749 Cr | 55.1x | — | 18.8% | 55.0x |
| HealthCare Global Enterprises LimitedHCG | ₹9,408 Cr | 513.0x | 8.0x | 2.8% | 49.9x |
| Sanofi India LtdSANOFI | ₹9,387 Cr | 25.4x | 12.0x | — | — |
| Jeena Sikho Lifecare LimitedJSLL | ₹8,968 Cr | 58.2x | 25.2x | 35.9% | 90.3x |
| PROCTER & GAMBLE HEALTH LIMITEDPGHL | ₹8,946 Cr | 29.2x | 14.4x | — | — |
| Jupiter Life Line Hospitals LimitedJLHL | ₹8,877 Cr | 46.3x | 5.9x | 12.2% | 34.5x |
| Blue Jet Healthcare LimitedBLUEJET | ₹8,659 Cr | 24.6x | 6.9x | 19.4% | 34.4x |
| STRIDES PHARMA SCIENCE LIMITEDSTAR | ₹8,552 Cr | 112.0x | 2.7x | 1.3% | 35.5x |
| Sequent Scientific LimitedVIYASH | ₹8,288 Cr | 531.0x | 4.1x | 0.1% | 633.5x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
CORONA since 1 January, against earlier years.
Historical volatility
CORONA's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 18.0% |
| FY2022 | 3.0% |
| FY2023 | 14.0% |
| FY2024 | 15.0% |
| FY2025 | 20.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,196 Cr |
| Costs | |
| Interest | ₹11 Cr |
| Expenses | ₹956 Cr |
| Operating profitOperating Profit | ₹241 Cr |
| Other income and charges | |
| Profit before tax | ₹198 Cr |
| Tax | |
| Net profitNet Profit | ₹149 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹929 Cr |
| Equity capitalEquity Capital | ₹61 Cr |
| Reserves | ₹545 Cr |
| Borrowings | ₹86 Cr |
| Other liabilitiesOther Liabilities | ₹237 Cr |
| AssetsTotal Assets | ₹929 Cr |
| Fixed assetsFixed Assets | ₹370 Cr |
| Capital work in progressCWIP | ₹186 Cr |
| Investments | ₹25 Cr |
| Other assetsOther Assets | ₹348 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹190 Cr |
| Investing cash flowCash from Investing Activity | -₹84 Cr |
| Financing cash flowCash from Financing Activity | -₹107 Cr |
| Change in cashNet Cash Flow | ₹0 Cr |
Learn while you research
Academy chapters picked for Corona Remedies Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 55.1, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read